A BILL to amend and reenact §§ 38.2-3465, 38.2-3467, and 38.2-3469 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 38.2-3467.1, relating to health insurance; pharmacy benefits management; requirements and prohibited conduct; retail pharmacy network access standards; enforcement; civil penalty.
HB1271 would significantly expand Virginia’s regulation of pharmacy benefits managers (PBMs) and carriers in the health insurance market. The bill revises statutory definitions related to PBM activity, rebates, spread pricing, retail pharmacy networks, and 340B-covered entities, and adds a new section imposing additional contract and disclosure requirements on PBMs. It also broadens the list of prohibited practices for carriers and PBMs, including misleading advertising, discriminatory reimbursement, retaliation against pharmacies, network participation fees, certain preferred-network restrictions, and the use of spread pricing.
The bill would require PBMs to disclose rebate and discount information to clients, provide access to contracts and utilization data upon request, maintain network-development records for three years, and submit quarterly reports. It also bars PBMs from restricting pharmacies from telling consumers about lower cash prices versus insurance prices, from limiting disclosures to regulators and law enforcement, and from requiring individuals to use PBM-affiliated pharmacies. In addition, it directs that mail order pharmacies and PBM affiliates not be counted toward network adequacy calculations.
HB1271 would strengthen enforcement by giving the State Corporation Commission primary enforcement authority while also authorizing the Attorney General to issue civil investigative demands, seek injunctions, and recover civil penalties of up to $5,000 per willful violation. The bill therefore creates new compliance obligations for PBMs and carriers and expands the state’s tools for oversight and enforcement of pharmacy network and pricing practices.
The overall sentiment reflected by the bill text and available context appears to be consumer- and pharmacy-protective, with the measure aimed at limiting PBM practices that can raise costs or restrict pharmacy choice. Because there were no recorded committee transcripts or votes, there is no direct evidence of debate or opposition in the provided materials, but the bill’s restrictions on PBM affiliates, spread pricing, and network design suggest likely tension with PBMs and insurers that rely on those business models.
The main points of contention are likely to center on whether the bill goes too far in regulating PBM contracting, pricing, and network management, and whether its disclosure and network-access rules would increase administrative burdens or reduce flexibility for carriers. On the other side, pharmacies, covered entities, and consumer advocates would likely support the bill’s efforts to improve transparency, prevent discriminatory reimbursement, and protect patient access to lower-cost pharmacy options.
HB1271 would amend Virginia Code §§ 38.2-3465, 38.2-3467, and 38.2-3469 and add § 38.2-3467.1, thereby expanding the state’s statutory framework governing PBMs and carrier pharmacy arrangements. It would impose new prohibitions on spread pricing, affiliate favoritism, discriminatory reimbursement, network participation fees, and certain restrictions on pharmacy choice, while also adding disclosure, recordkeeping, and reporting duties for PBMs. The bill also enhances enforcement authority for the State Corporation Commission and the Attorney General, including civil investigative demands, injunctions, and civil penalties.
The bill appears generally favorable toward pharmacies, covered entities, and consumers seeking transparency and lower prescription drug costs, while placing tighter limits on PBM and carrier conduct. No committee discussion or vote history is provided, so there is no recorded formal opposition or support in the materials, but the structure of the bill suggests it is intended as a reform measure aimed at PBM practices that are often criticized as opaque or anti-competitive.
Likely points of contention include the ban on spread pricing, the prohibition on requiring use of PBM-affiliated pharmacies, limits on counting mail-order and affiliate pharmacies toward network adequacy, and the requirement to disclose rebates, contracts, and utilization data. PBMs and carriers may view these provisions as intrusive or operationally burdensome, while pharmacies, 340B entities, and consumer advocates are likely to support them as necessary to prevent steering, improve transparency, and protect access to community pharmacies.